- Home
- DMRC vs PLX Comparison
DMRC vs PLX Comparison
Compare DMRC & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRC | PLX |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.3M | 207.1M |
| IPO Year | 2026 | 1996 |
Fundamental Metrics
Financial Performance| Metric | DMRC | PLX |
|---|---|---|
| Price | $7.08 | $2.55 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $11.50 | N/A |
| AVG Volume (30 Days) | 146.9K | ★ 840.6K |
| Earning Date | 11-02-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | $5.99 | N/A |
| P/E Ratio | ★ N/A | $9.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.07 | $1.65 |
| 52 Week High | $17.47 | $3.19 |
Technical Indicators
Market Signals| Indicator | DMRC | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 60.21 | 42.21 |
| Support Level | $7.06 | $2.21 |
| Resistance Level | $8.20 | $2.75 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 57.11 | 7.41 |
Price Performance
Historical ComparisonAbout DMRC Digimarc Corporation
Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.